Last updated on October 2017

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies


Brief description of study

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other agents in a Genentech/Roche-sponsored parent study who are active and deriving benefit at the closure of parent study are eligible for continued treatment in this study.

Clinical Study Identifier: NCT00781612

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: BO25430 ...

City Oncology Dispensary
St Petersburg, Russian Federation
  Connect »